In this 24-week , multicenter , randomized , double-blind , parallel-group , placebo controlled study , 173 patients were randomly assigned ( a 21 ratio ) to lobeglitazone 0.5 mg ( n = 115 ) or matching placebo ( n = 58 ) orally once daily .